& Total Voting Rights Futura Medical plc (AIM: FUM) ( Futura or the Company ), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, announces that it has received a conversion notice from HT Riverwood Multi-Growth Fund ( Riverwood ), a fund managed by Atlantis Investment Management Limited ( Atlantis ), in respect of £1.5 million in principal amount of the convertible loan notes issued by the Company on 4 March 2021. This notice represents the final conversion and following this there will be no further amounts outstanding to Riverwood. Pursuant to the conversion, the Company will issue, in aggregate, 7,500,000 new ordinary shares of 0.2 pence each in the capital of the Company (the Conversion Shares ) at a conversion price of 20 pence per Ordinary Share.
Guildford
Surrey
United-kingdom
London
City-of
James-barder
Angela-hildreth
Yang-liu
Strategic-communications
London-stock-exchange
Growth-fund-riverwood
Regulatory-information-service